Safety and efficacy of hetrombopag in patients with chronic immune thrombocytopenia: a single-arm, open-label, multi-center phase 1 study

BACKGROUND: Thrombopoietin receptor agonists (TPO‐RAs) are promising therapeutic strategy for patients with immune thrombocytopenia (ITP). We conducted this phase 1 trial (NCT02614846) to evaluate the preliminary efficacy and safety of hetrombopag (a TPO-RA) in patients with ITP. METHODS: Patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Mei, Heng, Chen, Xiequn, Zhou, Jianfeng, Luo, Jianmin, Shi, Qingzhi, Liu, Jing, Wu, Depei, Chen, Guoan, Tai, Yanfei, Xiong, Junye, Zou, Jianjun, Hu, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848441/
https://www.ncbi.nlm.nih.gov/pubmed/35282136
http://dx.doi.org/10.21037/atm-21-4361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848441/
https://www.ncbi.nlm.nih.gov/pubmed/35282136
http://dx.doi.org/10.21037/atm-21-4361

Ejemplares similares